Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One shot to stop cancer: HPV vaccine study could change global prevention

NCT ID NCT05237947

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either one HPV shot or a placebo to see if one dose is enough to prevent persistent HPV infections that can lead to cancer. If successful, this could simplify vaccination programs worldwide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * INCLUSION CRITERIA AT ENROLLMENT: Female. * INCLUSION CRITERIA AT ENROLLMENT: Aged between 18 and 30 years inclusive. * INCLUSION CRITERIA AT ENROLLMENT: Living in the study area. * INCLUSION CRITERIA AT ENROLLMENT: Able to communicate with study personnel. * INCLUSION CRITERIA AT ENROLLMENT: Willing to participate in the study and sign the informed consent. * INCLUSION CRITERIA AT ENROLLMENT: In good health as determined by a medical history (physical exam will be conducted if necessary per the doctor's criterion). * DEFERRAL CRITERIA AT ENROLLMENT VISIT: The enrollment visit will be deferred (i.e., rescheduled for another date) for participants if: the self-collected cervical sample is not able to be collected. * DEFERRAL CRITERIA AT THE VACCINATION VISIT: The vaccination visit will be deferred (i.e., rescheduled for another date) for participants if: * They have an acute disease that precludes vaccination (though vaccines can be administered to potential participants with a minor illness such as diarrhea and mild upper respiratory infection) * They are receiving immunosuppressive treatment, e.g. corticosteroids * They have received any registered vaccine in the last 15 days. Exclusion Criteria: * EXCLUSION CRITERIA AT ENROLLMENT VISIT: They have been vaccinated against human papillomavirus (HPV). * EXCLUSION CRITERIA AT ENROLLMENT VISIT: They are allergic to yeast or another vaccine components. * EXCLUSION CRITERIA AT ENROLLMENT VISIT: They have a diagnosis of an autoimmune, degenerative, or neurological disease without treatment or adequate control; a progressive or severe neurological disease; a genetic immunodeficiency; or any other serious chronic disease without treatment and / or adequate control that, according to the principal investigator or designee, for which vaccination is contraindicated. * EXCLUSION CRITERIA AT ENROLLMENT VISIT: They have plans to move outside the country in the next six months. * EXCLUSION CRITERIA AT ENROLLMENT VISIT: They refuse or are unable to self-collect the cervical sample. * EXCLUSION CRITERIA AT ENROLLMENT VISIT: They are pregnant. * EXCLUSION CRITERIA AT ENROLLMENT VISIT: They do not have an identification document. * EXCLUSION CRITERIA AT ENROLLMENT VISIT: The clinician determining eligibility in agreement with the principal investigator considers that there is a reason that precludes participation. * EXCLUSION CRITERIA AT VACCINATION VISIT: Between the enrollment and vaccine visit, they have been vaccinated against HPV. * EXCLUSION CRITERIA AT VACCINATION VISIT: Between the enrollment and vaccine visit, they are being evaluated for or have received a diagnosis of: an autoimmune, degenerative, or neurological disease without treatment or adequate control; a progressive or severe neurological disease; a genetic immunodeficiency; or any other serious chronic disease without treatment and/or adequate control, for which vaccination is contraindicated according to the principal investigator or designee. * EXCLUSION CRITERIA AT VACCINATION VISIT: They have plans to move outside the country in the next six months. * EXCLUSION CRITERIA AT VACCINATION VISIT: They refuse the urine pregnancy test. * EXCLUSION CRITERIA AT VACCINATION VISIT: They have a positive urine pregnancy test result. * EXCLUSION CRITERIA AT VACCINATION VISIT: They are pregnant. * EXCLUSION CRITERIA AT VACCINATION VISIT: They refuse or are unable to perform the self-collected cervical sample. * EXCLUSION CRITERIA AT VACCINATION VISIT: The clinician determining eligibility in agreement with the principal investigator considers that there is a reason that precludes participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human papillomavirus-related cervical carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Agencia Costarricense de Investigaciones Biomédicas (ACIB)

    Liberia, Guanacaste Province, 50101, Costa Rica

More trials for these conditions

Other studies related to the condition(s) this trial covers.